



D0250 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Melissa Handler, Ph.D.

June 20, 2007

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/621,807 Confirmation No. 1455
Applicant : Doweyko et al.
Filed : July 17, 2003
For: **COMPOSITIONS AND METHODS INVOLVING NUCLEAR HORMONE
RECEPTOR SITE II**
Art Unit : 1656
Examiner : Nashaat T. Nashed

Docket No. : D0250 NP
Customer No. : 23914

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

06/22/2007 WASFAW1 00000062 193800 10621807
01 FC:1464 130.00 DA

**PETITION UNDER 37 CFR § 1.84(a)(2)
REQUESTING ACCEPTANCE OF COLOR DRAWINGS**

Sir:


Applicants submit FIGS. 3 and 7 as color drawings. FIG. 7 illustrates a Glucocorticoid Receptor homology model displayed in ribbon format with dexamethasone (green) and Compound 15 (violet) displayed as space-filling models docked in Site I and Site II, respectively. FIG. 7 illustrates a ribbon diagram of the ligand binding domains of 11 NHRs detailed in Figure 2, based on a consensus alignment paradigm (ICM, Molsoft LLC, La Jolla, CA). Applicants believe the color drawings of FIGS. 3 and 7 are necessary as the only practical medium by which to disclose the subject matter sought to be patented in this utility patent application. However, a decision to grant this petition should not be regarded as an indication that color drawings are necessary to comply with a statutory requirement.

Applicants enclose herewith three sets of color drawings as required under 37 CFR § 1.84(a)(2)(ii). In addition, an amendment to the specification to insert the language required under 37 CFR § 1.84(a)(2)(iii) is provided in the enclosed Amendment and Response under 37 CFR § 1.111.

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$130 for payment of the fee set forth in 37 CFR § 1.17(h). An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR § 1.17 which may be required, or to credit any overpayment, to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-4323


Melissa Handler, Ph.D.
Agent for Applicants
Reg. No. 52,988

Date: June 20, 2007